Stereotactic body radiation therapy for stage I non-small cell lung carcinomas: moderate hypofractionation optimizes outcome

Surgery is the gold standard treatment in the management of stage I non-small cell lung carcinoma (NSCLC) and is resulting in a 5-year overall survival (OS) rate in the order of 60 to 80 % (1). The median age of patients presenting a stage I NSCLC is about 70 years. Thus, age and cardiopulmonary comorbidities may often contraindicate any surgical management. In this case or if the patient refuses surgery, one of the alternative is stereotactic body radiation therapy (SBRT) (2). Radiofrequency ablation is also a safe option for medically inoperable patients (3).

Source: Lung Cancer - November 15, 2018 Category: Cancer & Oncology Authors: I. Menoux, D. Antoni, P. Truntzer, A. Keller, G. Massard, G. No ël Source Type: research